ArticleDiabetology & metabolic syndrome2025
Sex differences in metabolic syndrome among U.S. adolescents, NHANES 1999-2020.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMetabolic syndrome (MS) poses a growing threat to adolescent health, yet its sex-specific patterns remain inadequately characterized. This study aimed to investigate sex differences in MS prevalence, risk factor clustering, and metabolic phenotypes among U.S. adolescents.
methodsWe analyzed cross-sectional data from 6,989 adolescents aged 12-19 years, representing 30.97 million U.S. adolescents, from the National Health and Nutrition Examination Survey (1999-2020). MS was defined based on abdominal obesity, elevated blood pressure, hyperglycemia, and dyslipidemia, using weighted analyses to account for complex survey design.
resultsThe overall MS prevalence was 5.1%, with a significantly higher prevalence in males than in females (6.1% vs. 4.1%, P = 0.017). Critically, no significant temporal trends in MS prevalence were observed over the 20-year period for either sex. Males accumulated more metabolic risk factors than females, showing higher rates of elevated BP (5.9% vs. 0.9%), fasting glucose (22.7% vs. 10.4%), and triglycerides (8.8% vs. 6.4%), whereas, females had higher prevalences of abdominal obesity (25.9% vs. 12.6%) and low HDL-C (22.8% vs. 18.8%). Moreover, metabolically unhealthy obesity was more common in males (13.7% vs. 10.0%). Subgroup analyses showed significant sex disparities persisted among ages 12-15, obese, non-Hispanic White, and high-income subgroups. Sensitivity analyses using alternative definitions, including waist-to-height ratio for abdominal obesity, robustly confirmed the male predominance in MS prevalence.
conclusionMale U.S. adolescents exhibited a higher MS prevalence and a more unfavorable aggregation of metabolic risk factors than females. The stability of MS prevalence over the two-decade period highlighted the need for sex-specific and developmentally targeted interventions, especially within identified high-disparity subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.